Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Unmet Needs in the Treatment of Lung Cancer

EP. 1: Introduction: Exploration of Nab-Paclitaxel in NSCLC

July 16th 2014

EP. 2: Nab-Paclitaxel in Non-Small Cell Lung Cancer

July 16th 2014

EP. 3: Maintenance Nab-Paclitaxel in Squamous NSCLC

July 16th 2014

EP. 4: Subgroup Analyses for Nab-Paclitaxel in NSCLC

July 16th 2014

EP. 5: Next-Generation EGFR Inhibitors in NSCLC

July 16th 2014

EP. 6: AZD9291 and Rociletinib in T790M-Mutant NSCLC

July 16th 2014

EP. 7: Afatinib Plus Cetuximab in Resistant NSCLC

July 16th 2014

EP. 8: Frontline ALK, EGFR Inhibition in NSCLC

July 16th 2014

EP. 9: Next-Generation ALK Inhibitors in NSCLC

July 16th 2014

EP. 10: Utilizing Next-Generation ALK Inhibitors in NSCLC

July 16th 2014

EP. 11: Efficacy of Next-Generation ALK Inhibitors

July 16th 2014

EP. 12: PD-1 Inhibition in Lung Cancer

July 16th 2014

EP. 13: Nivolumab in Non-Small Cell Lung Cancer

July 16th 2014

EP. 14: Multiple PD-1/PD-L1 Agents in Lung Cancer

July 16th 2014

EP. 15: PD-1/PD-L1 Inhibitors Across NSCLC Treatment Settings

July 16th 2014

EP. 16: Role of Maintenance Therapy in NSCLC

July 16th 2014

EP. 17: Maintenance Therapy Clinical Trials for NSCLC

July 16th 2014

EP. 18: PointBreak and AVAPERL Studies in NSCLC

July 16th 2014

EP. 19: Emerging Therapies in Non-Small Cell Lung Cancer

July 16th 2014

EP. 20: Novel Angiogenesis Inhibitors in NSCLC

July 16th 2014

EP. 21: Potential New Biomarkers in Lung Cancer

July 16th 2014

EP. 22: Conclusion: Addressing Unmet Needs in Lung Cancer

July 16th 2014
Advertisement
Advertisement

Trending on OncLive

1

FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC

2

PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings

3

META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL

4

Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL

5

CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us